Trifexis

RSS

spinosad / milbemycin oxime

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Trifexis has expired following the marketing-authorisation holder’s decision not to apply for a renewal.

This EPAR was last updated on 08/10/2018

Authorisation details

Product details
Name
Trifexis
Agency product number
EMEA/V/C/002635
Active substance
  • spinosad
  • milbemycin oxime
International non-proprietary name (INN) or common name
spinosad / milbemycin oxime
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QP54AB51
Publication details
Marketing-authorisation holder
Eli Lilly and Company Limited
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
19/09/2013
Contact address
Elanco Animal Health
Priestly Road
Basingstoke
Hampshire RG24 9NL
United Kingdom

Product information

17/02/2017 Trifexis - EMEA/V/C/002635 - II/0008

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Antiparasitic products
  • insecticides and repellents – endectocides

Therapeutic indication

For the treatment and prevention of flea (Ctenocephalides felis) infestations in dogs where one or more of the following indications are required concurrently:

 

  • prevention of heartworm disease (L3, L4 Dirofilaria immitis);
  • prevention of angiostrongylosis by reducing the level of infection with immature adult (L5) Angiostrongylus vasorum;
  • treatment of gastrointestinal nematode infections caused by hookworm (L4, immature adult, L5) and adult Ancylostoma caninum), roundworms (immature adult L5, and adult Toxocara canis and adult Toxascaris leonina) and whipworm (adult Trichuris vulpis).

 

Assessment history

How useful was this page?

Add your rating